- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.